Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyCarolina Behavioral Health CGM Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentCarolina Behavioral HealthPolicy 5A-3

    Continuous Glucose Monitoring Coverage and Prior Authorization Provider Guide

    Customize your policy alerts

    Sign up for carolinabehavioralhealth Policy 5A-3 alerts

    Get alerted when Policy 5A-3 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    NC Medicaid coverage and prior authorization requirements for FDA-approved therapeutic continuous glucose monitoring systems and supplies under the outpatient pharmacy benefit.

    Policy Summary
    PayerCarolina Behavioral Health
    PolicyContinuous Glucose Monitoring Coverage and Prior Authorization Provider Guide
    Policy CodePolicy 5A-3
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit CGM prior authorization requests through CoverMyMeds, by fax at 1-833-404-2393, or through the Pharmacy PA Call Center at 1-833-585-4309.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Therapeutic CGM product groups listed as covered
    6 monthsInitial authorization validity period
    Up to 12 monthsReauthorization period
    Under 21Beneficiaries subject to EPSDT provisions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1
    Therapeutic CGMs permitted at one time

    Therapeutic CGM Coverage Criteria

    Initial Therapy

    Covered when the beneficiary meets one of the following initial prior authorization pathways:

    ONE of the following pathways

    • Pathway A — criteria 1 through 3

      • The beneficiary has a diagnosis of insulin-dependent diabetes.
      • The beneficiary or caregiver(s) is willing and able to use the therapeutic CGM system as prescribed.
      • The beneficiary has had a face-to-face encounter with the treating practitioner to evaluate glycemic control and determine that criteria one through three have been met within six months of the initial authorization request.
    • Pathway B — criteria 1 and 4

      • The beneficiary has a diagnosis of insulin-dependent diabetes.
      • The beneficiary uses an external insulin pump.
    • The beneficiary has a diagnosis of gestational diabetes.

    Continuation Therapy

    Continuation therapy requires the applicable reauthorization documentation below. The first reauthorization may be approved for up to 12 months when documentation supports the criteria.

    First reauthorization — up to 12 months

    • Proper use of the therapeutic CGM device.
    • ONE of the following

      • Improved glycemic control.
      • Continued use of an insulin pump.

    Subsequent reauthorization

    • A face-to-face encounter with the treating practitioner occurred within three months of the reauthorization request.

    Only FDA-approved therapeutic CGM systems are covered under the outpatient pharmacy benefit. Non-therapeutic CGM systems are excluded from the outpatient pharmacy benefit and fall under DME coverage criteria in Clinical Coverage Policy 5A-3.

    Simultaneous use of more than one therapeutic CGM is not allowed.

    Product, Age, and Authorization Parameters

    Qualifying diagnosis notationICD-10
    E11.xxDiagnosis of insulin-dependent diabetes
    Dexcom G6 and G7
    Covered productsDexcom G6 and Dexcom G7
    Minimum coverage ageAges 2 and older
    Product categoryFDA-approved therapeutic CGM systems covered under the outpatient pharmacy benefit
    FreeStyle Libre 2 Plus and 3 Plus
    Covered productsFreeStyle Libre 2 Plus and FreeStyle Libre 3 Plus
    State coverage age requirementAges 4 and older
    Manufacturer and FDA age context

    Prior Authorization and Documentation

    Prior Authorization

    Initial Authorization Pathways

    For initial authorization, the beneficiary must meet either criteria 1–3, criteria 1 and 4, or criterion 5. The initial authorization is valid for 6 months once approved.

    • Criteria 1–3: insulin-dependent diabetes; willingness and ability of the beneficiary or caregiver to use the therapeutic CGM as prescribed; and a face-to-face treating-practitioner encounter within 6 months of the initial request evaluating glycemic control and confirming the criteria.
    • Criteria 1 and 4: insulin-dependent diabetes and use of an external insulin pump.
    • Criterion 5: gestational diabetes.
    Documentation Required

    First Reauthorization Requirements

    For the first reauthorization, submit documentation showing proper use of the CGM and either improved glycemic control or continued insulin pump use. Reauthorization may be approved for up to 12 months when the required documentation supports continued coverage.

    Therapeutic CGM Program Context

    Therapeutic continuous glucose monitoring (CGM) coverage applies to FDA-approved therapeutic systems and supplies for beneficiaries with insulin-dependent diabetes, those who use an external insulin pump, or those with gestational diabetes. The beneficiary or caregiver must be willing and able to use the device as prescribed.

    Key Terms

    EPSDT
    MeaningEarly and Periodic Screening, Diagnostic, and Treatment
    ApplicabilityMedicaid members under age 21
    Medical-necessity flexibilityCoverage may exceed policy limitations when services are medically necessary to correct or improve a health condition
    Therapeutic CGM
    DefinitionFDA-approved continuous glucose monitoring systems intended for therapeutic use
    Coverage settingOutpatient pharmacy benefit
    Coverage limitationNon-therapeutic systems are not covered under the outpatient pharmacy benefit and fall under DME criteria
    Policy Summary
    PayerCarolina Behavioral Health
    PolicyContinuous Glucose Monitoring Coverage and Prior Authorization Provider Guide
    Policy CodePolicy 5A-3
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit CGM prior authorization requests through CoverMyMeds, by fax at 1-833-404-2393, or through the Pharmacy PA Call Center at 1-833-585-4309.
    SourceLink
    On This Page
    Therapeutic CGM Coverage CriteriaProduct, Age, and Authorization ParametersPrior Authorization and DocumentationTherapeutic CGM Program ContextKey Terms
    Continued prescribed use of the therapeutic CGM system.
  1. ONE of the following

    • Maintenance or improvement in glycemic control.
    • Continued use of an insulin pump.
  2. Manufacturer guidelines and FDA approval support use in members ages 2 and older; state approval is pending
    FreeStyle Libre 14 Day
    Covered productFreeStyle Libre 14 Day
    Minimum coverage ageAges 18 and older
    Preferred-product statusNot a preferred product; trial and failure of preferred CGMs may be required along with clinical criteria
    Initial Authorization
    Authorization typeInitial prior authorization
    Authorization duration6 months
    Validity beginsOnce the initial prior authorization is approved
    Initial Face-to-Face Encounter
    Encounter typeFace-to-face encounter with the treating practitioner
    Timing requirementWithin 6 months of the initial authorization request
    Encounter purposeEvaluate glycemic control and determine that the applicable criteria have been met
    Subsequent Reauthorization Encounter
    Encounter typeFace-to-face encounter
    Timing requirementWithin 3 months of the reauthorization request
    Related continuation documentationDocument continued prescribed use and maintenance or improvement in glycemic control, or continued use of an insulin pump
    Reauthorization Duration
    Authorization typeReauthorization
    Maximum durationUp to 12 months
    Documentation basisProper or continued prescribed device use plus the applicable glycemic-control outcome or continued insulin-pump use
    • Proper use of the device
    • Improved glycemic control, or continued use of an insulin pump
    • Reauthorization period: up to 12 months
    Prior Authorization

    Subsequent Reauthorization

    Subsequent reauthorization requests must document ongoing clinical eligibility and compliance with therapy. A face-to-face encounter must occur within 3 months of the request, and simultaneous use of more than one therapeutic CGM is not allowed.

    • Face-to-face encounter within 3 months of the request
    • Continued prescribed use
    • Maintenance or improvement in glycemic control, or continued use of an insulin pump
    • Do not use more than one therapeutic CGM simultaneously
    Prior Authorization

    Submit the PA Request

    Submit CGM prior authorization requests through an approved route and include the required clinical documentation and form when submitting by fax.

    • CoverMyMeds®: https://www.covermymeds.health/prior-authorization-forms
    • Fax: 1-833-404-2393 using the CGM Prior Approval Request Form
    • Pharmacy PA Call Center: (833) 585-4309
    • Forms and submission information: https://network.carolinacompletehealth.com/resources/pharmacy/outpatient-pharmacy-benefit.html
    Prior Authorization

    EPSDT Prior Authorization

    Prior authorization remains required for Medicaid beneficiaries under age 21, including when EPSDT provisions apply. EPSDT medical necessity may permit flexibility beyond policy limitations in the scope or frequency of services when needed to correct or improve a health condition.

    • Confirm PA approval before dispensing or providing the CGM for beneficiaries under 21.
    • Apply EPSDT medical-necessity requirements when requesting coverage beyond standard policy limitations.
    • Use the EPSDT Provider Page and NCTracks Provider Manuals for applicable guidance.
    Step Therapy

    Nonpreferred Libre 14 Day

    FreeStyle Libre 14 Day is a nonpreferred therapeutic CGM. Its coverage may require trial and failure of a preferred CGM in addition to meeting the applicable clinical criteria.

    • Nonpreferred product: FreeStyle Libre 14 Day
    • Age requirement: 18 years and older
    • Preferred alternatives include Dexcom G6/G7 and FreeStyle Libre 2 Plus/3 Plus, subject to applicable age and coverage requirements
    Documentation Required

    Initial Request Documentation

    For an initial request, document a qualifying clinical pathway, the beneficiary’s or caregiver’s ability and willingness to use the therapeutic CGM as prescribed, and the required treating-practitioner evaluation when applicable.

    • Insulin-dependent diabetes with a face-to-face glycemic-control evaluation within 6 months of the request; or
    • Insulin-dependent diabetes plus use of an external insulin pump; or
    • Gestational diabetes
    • Document beneficiary or caregiver willingness and ability to use the device as prescribed
    Documentation Required

    First Reauthorization Documentation

    The first reauthorization request must include documentation of proper device use and either improved glycemic control or continued insulin pump use. Without this evidence, continued authorization may not be supported.

    • Document proper use of the CGM
    • Document improved glycemic control, or continued insulin pump use
    Documentation Required

    Subsequent Reauthorization Documentation

    For subsequent reauthorization, provide evidence of a timely face-to-face encounter, continued prescribed use, and ongoing clinical benefit or qualifying pump use. Confirm that the beneficiary is not using more than one therapeutic CGM at the same time.

    • Face-to-face encounter within 3 months of the request
    • Continued prescribed use
    • Maintenance or improvement in glycemic control, or continued insulin pump use
    • No simultaneous use of multiple therapeutic CGMs
    Denial Risk

    Common Denial Triggers

    Requests may be denied or delayed when the product is not covered, required step therapy or clinical criteria are not met, or authorization and documentation conditions are incomplete.

    • Nonpreferred or noncovered product without required trial-and-failure documentation
    • Missing diagnosis, external insulin-pump use, or gestational-diabetes pathway
    • Missing beneficiary or caregiver ability and willingness to use the device as prescribed
    • Missing required face-to-face encounter or glycemic-control documentation
    • Concurrent use of more than one therapeutic CGM

    Unsupported block type: documentation